Methylated MGMT status is recognized as the most robust predictive marker in patients with GBM; however, there is insufficient evidence regarding the impact of CDKN2A homozygous deletion on OS for IDH‐wildtype GBM, and therefore, its prognostic impact remains controversial.20 This evidence concerns the gene IDH1 and glioblastoma.